NewAmsterdam Pharma

NewAmsterdam Pharma is a late-stage biopharmaceutical company that develops oral, non-statin therapies for patients with cardiometabolic diseases, especially those at risk of cardiovascular disease with elevated LDL cholesterol. Its lead candidate is obicetrapib, a CETP inhibitor, which is being studied as a monotherapy and in a fixed-dose combination with ezetimibe. The company says its mission is to improve care for millions of patients who are not served by current therapies.